Leaman John Harold 4

What Happened

• John Harold Leaman, a director of Traws Pharma, was granted 33,435 stock options on 2026-03-08. The reported acquisition price is $0.00 (derivative award), so there was no cash exchanged. The award is classified as an option/award rather than a purchase or sale.

Key Details

• Transaction date: 2026-03-08; Filing date: 2026-03-10 (timely Form 4 filing).
• Type: Award/Grant of derivative securities (stock options), 33,435 options; reported price $0.00; reported total value $0.
• Vesting: Per footnote, the options vest 100% on the first anniversary of the grant (i.e., fully vest on 2027-03-08).
• Award authority: Granted by the issuer’s compensation committee composed of independent directors.
• Shares owned after transaction: Not specified in the filing.
• No 10b5-1 plan, tax withholding, or sale reported in this filing.

Context

• This is a compensation award (not a market purchase or sale). Options vest in one year; only after vesting and exercise would they convert to common shares or potentially be sold. Such grants are routine for directors as part of equity compensation and do not by themselves indicate immediate buying or selling intent.